Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study

Abstract Introduction The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in patients with migraine who are treated with mAbs....

Full description

Bibliographic Details
Published in:	Neurology and Therapy
Main Authors:	Taoufik Alsaadi, Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Princess Carmina, Batool Aldaher, Shadi Haddad, Yazan Bader
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-02-01
Subjects:	CGRP mAbs Erenumab Eptinezumab Gepants Migraine Safety
Online Access:	https://doi.org/10.1007/s40120-024-00586-w

Similar Items

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
by: Yazan Bader, et al.
Published: (2023-07-01)

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
by: Marta Waliszewska-Prosół, et al.
Published: (2023-12-01)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
by: Theodoros Mavridis, et al.
Published: (2021-07-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

Gepants for abortive treatment of migraine: A network meta‐analysis
by: Peiwei Hong, et al.
Published: (2020-08-01)

Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study
by: Piero Barbanti, et al.
Published: (2024-06-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity
by: Edward Griffin, et al.
Published: (2024-04-01)

CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine
by: Francesca Finelli, et al.
Published: (2024-01-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Blocking CGRP in migraine patients – a review of pros and cons
by: Marie Deen, et al.
Published: (2017-09-01)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
by: Bianca Raffaelli, et al.
Published: (2023-02-01)

Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment
by: Marcin Straburzyński, et al.
Published: (2025-04-01)

Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics
by: Deirdre M. Boucherie, et al.
Published: (2024-08-01)

Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence
by: Abubker Omaer, et al.
Published: (2024-04-01)

Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE
by: Taoufik Alsaadi, et al.
Published: (2023-10-01)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
by: Antun R. Pavelic, et al.
Published: (2022-12-01)

Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea
by: Anna V. Berdnikova, et al.
Published: (2023-10-01)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01)

A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
by: Caroline S. Casey, et al.
Published: (2025-04-01)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
by: Altamura C, et al.
Published: (2023-11-01)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
by: Cohen F, et al.
Published: (2022-04-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
by: Giuseppe Tringali, et al.
Published: (2020-10-01)

Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study
by: Reem Suliman, et al.
Published: (2024-02-01)

Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study
by: Bui Bao Khanh Dinh, et al.
Published: (2021-12-01)

Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine
by: David Moreno-Ajona, et al.
Published: (2020-09-01)

Progress in treating migraines: promising prospects for a better tomorrow
by: Seyed-Amirabbas Ahadiat, et al.
Published: (2023-08-01)

Blocking the CGRP Receptor: Differences across Human Vascular Beds
by: Tessa de Vries, et al.
Published: (2023-07-01)

CGRP en migraña: de la fisiopatología a la terapéutica
by: S. Santos-Lasaosa, et al.
Published: (2022-06-01)

Rimegepant - a breakthrough drug for migraine treatment - literature review
by: Katarzyna Kuleta, et al.
Published: (2024-08-01)

Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
by: Keiko Ihara, et al.
Published: (2023-03-01)

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
by: Danuta Szkutnik-Fiedler
Published: (2020-12-01)

Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)
by: Luigi Francesco Iannone, et al.
Published: (2025-01-01)

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data
by: N. V. Vashchenko, et al.
Published: (2022-01-01)

Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis
by: Mohamed E. Haseeb, et al.
Published: (2025-03-01)

Expert consensus on gepants for acute and preventive treatment of migraine in Thailand
by: Prakit Anukoolwittaya, et al.
Published: (2025-06-01)

Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)
by: Taoufik Alsaadi, et al.
Published: (2024-01-01)

Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study
by: Patricia Pozo-Rosich, et al.
Published: (2024-01-01)